Eptazzo
(Gemigliptin)ApprovedSmall molecule
Gemigliptin is used to treat type 2 diabetes by helping the pancreas release more insulin and controlling blood sugar levels in patients whose blood sugar cannot be controlled by diet and exercise alone.[2] Eptazzo is currently approved and in use across 8 indications[4].[1]
Eptazzo is one of 254 small molecule programs targeting Calcification. It is currently in Approved.
8
Indications
22
Total Trials
0
Active Trials
253
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Eptazzo
LLG Chem
Approved
Byetta
AstraZenecaPreclinical
Jardiance
Boehringer IngelheimPreclinical
NOVOLIN R
Novo NordiskPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes4 trials
Metformin2 trials
Interaction2 trials
Efficacy and Safety2 trials
10 more indications
Endothelial Function1 trial
Observational Study1 trial
Hepatic Impairment1 trial
Calcification1 trial
Gemigliptin and Biomarkers of Kidney Injury and Vascular Calcification
Completed·—·N/A·NCT04705506·201 enrolled
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Eptazzo drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Gemigliptin. EMBL-EBI & Wellcome Sanger Institute.
- [5]